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Low-density lipoproteins activate isolated human platelets. The mechanism of this activation is unknown, but may invol- 
ve increased phosphoinositide turnover. We have examined the effect of low-density lipoproteins on intracellular calcium 
concentrations in platelets loaded with the photoprotein aequorin. The lipoproteins induced concentration-dependent 
increases in intracellular calcium, associated with shape change and aggregation. These responses could be partially inhib- 
ited by the removal of extracellular calcium and by pre-incubation with acetylsalicylic acid. They were also antagonised 
by agents which increase cellular concentrations of cyclic adenosine and guanosine monophosphates. It is not clear 
whether the platelet-lipoprotein interaction involves a ‘classical’ lipoprotein receptor. 
LDL; intracellular Caz+; Aequorin; (Human platelet) 
1. INTRODUCTION 
There is considerable evidence that platelets 
from hypercholesterolaemic patients are abnor- 
mally sensitive to several agonists in vitro [1,2]. 
These patients have elevated levels of circulating 
thromboxane BZ and &thromboglobulin, sug- 
gesting that in vivo platelet activation may also be 
abnormal [3]. The abnormal platelet activation ap- 
pears to be related to high blood levels of LDL and 
VLDL, particularly the former [4], and LDL has 
been shown in vitro to be a platelet activator in its 
own right [5]. The mechanism of the LDL-platelet 
interaction is poorly understood. However, it is 
known that there are specific binding sites for LDL 
on the platelet [6] and that LDL causes early ac- 
tivation of the cycle-oxygenase pathway, increased 
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diacylglycerol concentrations, and the phospho- 
rylation of 47 kDa proteins [7]. This may be 
associated with enhanced membrane phosphoino- 
sitide turnover, which would usually involve an in- 
crease in [Cali. We have examined the [Cali 
response to LDL in isolated human platelets using 
the photoprotein aequorin. The more commonly 
used fluorescent calcium probes, such as quin-2 
and fura-2, could not be used satisfactorily in these 
experiments because of the intense autofluo- 
rescence of LDL itself at physiological concen- 
trations. 
2. MATERIALS AND METHODS 
2.1. Materials 
Aequorin was purchased from Dr J. Blinks, Mayo Clinic, 
Rochester, MA. Nifedipine was a gift from Bayer, England. 
HL725 was from Calbiochem. Other chemicals were from 
Sigma or British Drug Houses Ltd. 
2.2. Preparation of LDL 
LDL was prepared by differential ultracentrifugation from 
the fresh plasma of normal volunteers by a modification of the 
method of Chung et al. [8]. After extensive dialysis the LDL 
was concentrated to a protein concentration of 15-30 g LDL/l. 
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Until the final period of dialysis EDTA was present to minimise 
LDL oxidation. The loading procedure was modified from 
those of Vickers and Mustard [9] and of Johnson et al. [lo]. All 
procedures were performed at room temperature. Fresh blood 
(usually 20 ml) was anticoagulated with 3.15% trisodium citrate 
(9: 1 by vol.). The blood was centrifuged at 180 x g for 15 min 
at room temperature and the platelet-rich plasma (PRP) was 
removed. Forskolin (10 FM) was added and the PRP was cen- 
trifuged at 600 x g for 10 min at room temperature: all the 
following procedures were also performed at room 
temperature. The plasma was removed as completely as possible 
and the pellet resuspended in a hypotonic loading buffer [9], to 
which EGTA (10 mM final concentration) was added. After 
10 min, disodium ATP (5 FM) and aequorin (17.5 ~1 of a 3 g/l 
solution) was added. 5 min later, 42 ~1 hypertonic buffer and 
2.5 ~1 of 200 mM magnesium chloride were added. After a fur- 
ther 15 min, the platelet suspension was filtered through a 
Sepharose CL-4B column pre-equilibrated with a modified 
Hepes-Tyrode’s buffer. The gel filtered platelets were then 
made up to 20 ml with buffer (at a platelet concentration of 
about 2.5 x 10” cells/l) and calcium chloride (to 1 mM) was 
added. The platelets were used after a further 30 min equilibra- 
tion, with or without 0.1 mM acetylsalicylic acid. 
2.3. Measurement of platelet responses 
Platelet aggregation and luminescence responses were record- 
ed using a Chrono-Log PICA lumiaggregometer (Coulter Elec- 
tronics). [Cali values were calculated as described by Johnson 
et al. [lo], but assuming an intracellular magnesium concentra- 
tion of 0.1 mM [ll]. Where appropriate, potential antagonists 
were added 2 min before stimulation with LDL. 
3. RESULTS 
LDL caused a concentration-dependent increase 
in [Cali in isolated human platelets (fig.1). For 
comparison, an aggregatory concentration of 
thrombin (0.5 U/ml) produced a mean [Cali of 
9.1 PM (+ 0.8, n = 9). Low LDL concentrations 
(0.25-0.5 g/l) induced only shape change, whereas 
higher concentrations (20.75 g/l) induced both 
shape change and secondary aggregation. In some 
instances the two phases of the platelet response 
coincided with two peaks in the luminescence 
signal. In most experiments, however, only a single 
peak was observed in the luminescence trace, cor- 
responding to the shape change at low concentra- 
tions of LDL and to the aggregation response at 
higher LDL concentrations. Addition of 2.5 mM 
EGTA to the platelet suspension immediately 
before stimulation with LDL (1 g/l) reduced the 
[Cali by about 30% and inhibited secondary ag- 
gregation, without affecting 
(fig.2). 
the shape change 
Preincubation with 0.1 mM acetylsalicylic acid 
also reduced the peak [Cali response to LDL 
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Fig. 1. Concentration-response curve for LDL-induced increase 
in [Cali in aequorin-loaded platelets. Points are means f SE 
(n = 11-18). 
(1 g/l) by about 20% and abolished or reduced 
secondary aggregation (fig.3). LDL-induced ac- 
tivation, both the shape change and the increase in 
Q b 
Fig.2. Platelet [Cali and aggregation responses to 1 g/l LDL (a) 
in the presence of 2.5 mM EGTA added immediately before 
LDL and (b) without EGTA, in the presence of 1 mM Ca’+. 
Arrow indicates addition of LDL. Figures above luminescence 
peaks are [Cali (1IM). Each trace is representative of 4 
experiments. 
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Fig.3. Platelet [Cali and aggregation responses to 1 g/l LDL (a) 
with preincubation for 30 min with 100 ,uM acetylsalicylic acid 
and (b) without acetylsalicylic acid. Arrow indicates addition of 
LDL. Figures above luminescence peaks are [Cali @M). Each 
trace is representative of 6 experiments. 
[Cali, was completely inhibited by the cyclic AMP 
phoshodiesterase inhibitor HL725 (1 PM) [12] and 
by the permeant cyclic GMP analogue &bromo- 
cyclic GMP (1OOpM) (n = 3 for each). Two 
calcium channel blockers, nifedipine and diltiazem 
(each at lOpM), which have been reported to in- 
hibit in vitro platelet activation by other agonists 
such as adenosine diphosphate and arachidonic 
acid [13], failed to influence the calcium and ag- 
gregation responses to LDL (n = 4 for each). All 
the above compounds were incubated with the 
platelet suspension for 2 min before the addition 
of LDL. 
4. DISCUSSION 
Our results confirm that LDL produces a 
concentration-dependent activation of isolated 
human platelets, as judged by shape change and 
aggregation. We have also shown that this activa- 
tion is accompanied by an increase in [Cali which 
approximately parallels the extent of activation. 
Some of the rise in [Cali is due to influx from the 
external medium, since it can be partially inhibited 
by EGTA: longer pre-incubation with EGTA may 
have produced more marked inhibition. However, 
some of the calcium must originate from in- 
tracellular stores. It would be anticipated that such 
calcium mobilisation may be associated with 
enhanced phosphoinositide turnover, and 
preliminary experiments using platelets prelabelled 
with 3H-inositol suggest that this is the case 
(Tranter, unpublished). Earlier studies, using “P- 
labelled phospholipids, had failed to demonstrate 
significant breakdown of phosphatidylinositol 
4,5-bisphosphate [14]. This probably reflects the 
greater sensitivity of the inositol-labelling techni- 
que as an index of phosphoinositide turnover, and 
perhaps the small magnitude of the LDL-induced 
hydrolysis. It should be noted that the [Cali in- 
crease in response to LDL (up to 2 g/l) was much 
smaller than that to thrombin (0.5 U/ml), though 
LDL (l-2 g/l) consistently induces secondary ag- 
gregation. 
Since acetylsalicylic acid is an effective but in- 
complete inhibitor of LDL-induced activation, we 
agree with earlier findings that some of the activa- 
tion is due to a cycle-oxygenase product, probably 
thromboxane AZ [7]. This will itself promote 
calcium mobilisation and influx by a 
phosphoinositide-linked mechanism. The in- 
hibitory effects of increased cyclic nucleotide 
levels, though this is only inferred in the case of 
phosphodiesterase inhibition, are similar to in- 
teractions with other platelet agonists. In these 
cases it is thought that elevated levels of cyclic 
nucleotides may inhibit phosphoinositide 
breakdown and also promote the removal of free 
calcium from the cytoplasm, probably into mem- 
brane binding sites [ 151. LDL itself inhibits the 
prostacyclin-induced synthesis of cyclic nucleo- 
tides [16]. The lack of effect of the two calcium 
channel blockers is interesting as these drugs are 
widely used in the therapy of cardiovascular 
disease. Higher concentrations of these com- 
pounds may be inhibitory, but would have been 
very much higher than plasma levels attained in 
clinical practice. The mechanism of action of 
359 
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calcium channel blockers is unclear even in in- 
stances where they appear to be effective antiag- 
gregants: there do not appear to be any 
voltage-dependent calcium channels in the platelet, 
though extracellular calcium is obviously very im- 
portant for normal platelet function. 
Our findings differ in several respects from the 
results of Block and co-workers [18,19]. They also 
found that LDL increased [Cali and phos- 
phoinositide breakdown in the human platelet, 
though they used quin-2 as an indicator of free 
calcium concentration. This proved to be possible 
because of the very low concentrations of LDL 
used in their study (10 mg protein/l). However, 
in our series of experiments we have not seen 
detectable calcium or shape-change responses at 
LDL concentrations below 50 mg/l: occasionally 
responses were seen at a concentration of 100 
mg/l, while consistent responses were only ob- 
tained at concentrations greater than 250 mg/l. It 
is not clear whether this discrepancy is related to 
different techniques for the preparation of LDL or 
to some other technical factor. Furthermore, the 
LDL-induced increases in [Cali described by Block 
and colleagues are comparable to those produced 
by thrombin, though it should be noted that the 
concentration of thrombin used in their studies 
(0.1 U/ml) was lower than that in our experiments. 
We found a much greater discrepancy between 
[Cali responses to these agonists, even at LDL con- 
centrations as high as 2 g/l, and it may be surpris- 
ing that relatively modest increases in [Cali can be 
associated with secondary aggregation responses. 
As might be expected the absolute values of [Cali 
reported by aequorin are much higher than those 
with fluorescent indicators, even with a revised 
estimate of intracellular magnesium concentration. 
The reasons for this remain unclear. 
In conclusion, we have shown that LDL may ac- 
tivate human platelets partly by modestly increas- 
ing [Cali, possibly by enhancing phosphoinositide 
breakdown and by generating cyclooxygenase- 
derived secondary agonists. We have yet to 
establish whether this response is mediated by the 
type of LDL receptor described by Brown and 
Goldstein [20]. 
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